{"body":"<p><strong>A5.12 Quinine<\/strong><\/p>&#13;\n&#13;\n<p><strong>Therapeutic indications <\/strong><\/p>&#13;\n&#13;\n<p>Parenteral quinine is indicated for the treatment of severe malaria. Oral quinine is used in the treatment of uncomplicated malaria, particularly in the first trimester of pregnancy, or as an alternative treatment when an effective ACT is not promptly available.<\/p>&#13;\n&#13;\n<p><strong>Structure and mechanism of action<\/strong><\/p>&#13;\n&#13;\n<p>Quinine is an alkaloid derived from the bark of the cinchona tree that belongs to the aryl amino alcohol group of drugs (1). It is one of four antimalarial cinchona alkaloids and is the L-stereoisomer of quinidine. Quinine kills large ring and trophozoite asexual parasites and is gametocytocidal against <em>P. vivax, P. ovale and P. malariae<\/em> but not <em>P. falciparum<\/em> malaria (2). The mechanism of action of quinine is not clearly understood, although it is thought to involve inhibition of parasite haem detoxification inside the food vacuole.<\/p>&#13;\n&#13;\n<p><img alt=\"\" src=\"data:image\/gif;base64,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\" style=\"height=624;width=1024\" \/><\/p>&#13;\n&#13;\n<p><strong>Pharmacokinetics <\/strong><\/p>&#13;\n&#13;\n<p>The pharmacokinetic parameters of quinine are presented in Table A5.12 (2\u201333). Quinine is rapidly absorbed after both oral and parenteral administration. It is widely distributed throughout the body and is detectable in cerebrospinal fluid, breast milk and the placenta (2). Quinine undergoes extensive hepatic biotransformation, predominantly via CYP3A4 enzymes as well as CYP2C9, CYP1A2 and CYP2D6, into several metabolites. Quinine is both a substrate and an inhibitor of CYP2D6. The initial metabolite, 3-hydroxyquinine, contributes approximately 10% of the antimalarial activity of the parent compound. Up to 20% of administered drug is excreted unchanged by the kidneys, and small amounts may appear in bile and saliva (34, 35).<\/p>&#13;\n&#13;\n<p><strong>Table A5.12. Pharmacokinetic parameters of quinine reported with currently recommended doses used for the treatment of patients with severe or uncomplicated malaria (range of mean or median values reported). <\/strong><\/p>&#13;\n&#13;\n<p><img alt=\"\" src=\"data:image\/gif;base64,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\" style=\"height=308;width=1024\" \/><\/p>&#13;\n&#13;\n<p>The pharmacokinetics of quinine is altered significantly by malaria infection (2\u20134). Both the apparent volume of distribution and systemic clearance are reduced in proportion to disease severity, resulting in higher plasma quinine levels in patients with severe malaria. As a result, quinine accumulates with standard maintenance dosing regimens (10 mg salt\/kg bw every 8 h), unless the patient starts to recover. As a consequence, if there is no clinical recovery within 48 h, the dosage is reduced by one third (to 10 mg salt\/kg bw every 12 h). In patients who are in acute renal failure, quinine clearance is determined by the overall disease severity and hepatic function. In addition, plasma-protein binding, mainly to the acute-phase protein \u03b11-acid glycoprotein, increases from about 80% in healthy subjects to around 90% in patients with malaria (36).<\/p>&#13;\n&#13;\n<p>The exposure of pregnant women to quinine was generally lower and elimination more rapid than that in non-pregnant patients (23, 28). The disposition of quinine changes with age, with slightly higher concentrations observed in children &lt; 2 years (24). In children with protein energy malnutrition, clearance is significantly reduced, the elimination half-life is significantly longer but the maximum concentration significantly lower than in controls (20, 31, 32). Quinine pharmacokinetics, including total clearance normalized to ideal body weight, is not significantly altered in obese patients; thus, the maintenance dose of quinine in these patients should be based on ideal body weight rather than on total body weight (6, 33). Quinine clearance is significantly lower in elderly patients, posing a potential risk for drug accumulation and toxicity (26).<\/p>&#13;\n&#13;\n<p><strong>Safety <\/strong><\/p>&#13;\n&#13;\n<p><em><strong>Adverse events<\/strong><\/em><\/p>&#13;\n&#13;\n<p>Because of its narrow therapeutic index, quinine has frequent adverse effects (2, 6, 8, 28, 37). The side-effects commonly seen after administration of treatment doses are referred to as \u201ccinchonism\u201d. Mild forms are characterized by tinnitus, slight impairment of hearing, headache, nausea, dizziness, dysphoria and sometimes disturbed vision. Impairment of high tone hearing is usually concentration- dependent and reversible. More severe manifestations include vertigo, vomiting, abdominal pain, diarrhoea, marked auditory loss and visual symptoms, including loss of vision. An important side-effect of quinine is hyperinsulinaemic hypoglycaemia, which is particularly common in young children, pregnant women and elderly patients. Quinine also causes prolongation of the QTc interval (typically by about 10%), although cardiotoxic effects are much less frequent than those of quinidine. Hypotension and cardiac arrest may occur if the drug is given too rapidly (such as in an intravenous bolus); intravenous formulations should therefore be given by infusion not exceeding a rate of 5 mg\/kg bw per hour. Venous thrombosis may occur after intravenous administration, while pain, necrosis and abscess formation may occur with acidic intramuscular injections. Hypersensitivity reactions to quinine have also been reported, including urticaria, bronchospasm, flushing of the skin, fever, antibody-mediated thrombocytopenia, haemolytic anaemia and haemolytic\u2013uraemic syndrome. Hepatic injury and psychosis occur very rarely.<\/p>&#13;\n&#13;\n<p>Quinine has been used as an abortifacient, but there is no evidence that it causes abortion, premature labour or fetal abnormalities (28, 34). Quinine therefore remains the drug of choice during the first trimester of pregnancy. It may also be used safely in the second and third trimesters of pregnancy, although poor compliance because of 7-day treatment course and low tolerability may compromise its efficacy, and there is a high rate of hyperinsulinaemic hypoglycaemia.<\/p>&#13;\n&#13;\n<p>Overdosage of quinine may cause oculotoxicity, including blindness from direct retinal toxicity, and cardiotoxicity, and can be fatal (38). Cardiotoxic effects include conduction disturbances, angina and hypotension leading to cardiac arrest. Treatment is largely supportive, with particular attention to maintenance of blood pressure, glucose and renal function and to treating any arrhythmias.<\/p>&#13;\n&#13;\n<p><em><strong>Contraindications<\/strong><\/em><\/p>&#13;\n&#13;\n<p>Quinine is contraindicated in patients with known hypersensitivity to quinine or any of the cinchona alkaloids.<\/p>&#13;\n&#13;\n<p><em><strong>Caution <\/strong><\/em><\/p>&#13;\n&#13;\n<p>Although caution should be exercised when administering quinine to patients who have heart rhythm disorders or heart disease, there is little evidence of cardiotoxicity in patients with malaria. Quinine metabolites may cause oxidative haemolysis in people with G6PD deficiency. Caution is also advised in treating patients with kidney or liver disease, as the drug may accumulate (10, 18, 19, 39\u201341).<\/p>&#13;\n&#13;\n<p><em><strong>Drug interactions <\/strong><\/em><\/p>&#13;\n&#13;\n<p>See Table A5.14.<\/p>&#13;\n&#13;\n<p><strong>References<\/strong><\/p>&#13;\n&#13;\n<p>1. Cinchona bark. http:\/\/historyofmalaria.com\/2010\/02\/cinchona-bark\/.<\/p>&#13;\n&#13;\n<p>2. Achan, JT, Erhart A, Yeka A, Tibenderana JK, Baliraine FN, Rosenthal PJ, et al. Quinine, an old anti-malarial drug in a modern world: role in the treatment of malaria. Malar J 2011;10:144.<\/p>&#13;\n&#13;\n<p>3. Supanaranond W, Davis TM, Pukrittayakamee S, Silamut K, Karbwang J, Molunto P, et al. Disposition of oral quinine in acute falciparum malaria. Eur J Clin Pharmacol 1991;40:49\u201352.<\/p>&#13;\n&#13;\n<p>4. Sowunmi A. Disposition of oral quinine in African patients suffering from acute uncomplicated falciparum malaria. East Afr Med J 1996;73:519\u201323.<\/p>&#13;\n&#13;\n<p>5. Babalola CP, Bolaji OO, Ogunbona FA, Sowunmi A, Walker O. Pharmacokinetics of quinine in African patients with acute falciparum malaria. Pharm World Sci 1998;20:118\u201322.<\/p>&#13;\n&#13;\n<p>6. Claessen FA, van Boxtel CJ, Perenboom RM, Tange RA, Wetsteijn JC, Kager PA. Quinine pharmacokinetics: ototoxic and cardiotoxic effects in healthy Caucasian subjects and in patients with falciparum malaria. Trop Med Int Health 1998;3:482\u20139.<\/p>&#13;\n&#13;\n<p>7. Davis TM, White NJ, Looareesuwan S, Silamut K, Warrell DA. Quinine pharmacokinetics in cerebral malaria: predicted plasma concentrations after rapid intravenous loading using a two-compartment model. Trans R Soc Trop Med Hyg 1988;82:542\u20137.<\/p>&#13;\n&#13;\n<p>8. Dyer JR, Davis TM, Giele C, Annus T, Garcia-Webb P, Robson J. The pharmacokinetics and pharmacodynamics of quinine in the diabetic and non- diabetic elderly. Br J Clin Pharmacol 1994;38:205\u201312.<\/p>&#13;\n&#13;\n<p>9. Hendriksen IC, Maiga D, Lemnge MM, Mtove G, Gesase S, Reyburn H, et al. Population pharmacokinetic and pharmacodynamic properties of intramuscular quinine in Tanzanian children with severe falciparum malaria. Antimicrob Agents Chemother 2013;57:775\u201383.<\/p>&#13;\n&#13;\n<p>10. Karbwang J, Thanavibul A, Molunto P, Na Bangchang K. The pharmacokinetics of quinine in patients with hepatitis. Br J Clin Pharmacol 1993;35:444\u20136.<\/p>&#13;\n&#13;\n<p>11. Krishna S, Nagaraja NV, Planche T, Agbenyega T, Bedo-Addo G, Ansong D, et al. Population pharmacokinetics of intramuscular quinine in children with severe malaria. Antimicrob Agents Chemother 2001;45:1803\u20139.<\/p>&#13;\n&#13;\n<p>12. Krishna S, White NJ. Pharmacokinetics of quinine, chloroquine and amodiaquine. Clinical implications. Clin Pharmacokin 1996;30:263\u201399.<\/p>&#13;\n&#13;\n<p>13. Le Jouan M, Jullien V, Tetanye E, Tran A, Rey E, Treluyer JM, et al. Quinine pharmacokinetics and pharmacodynamics in children with malaria caused by <em>Plasmodium falciparum<\/em>. Antimicrob Agents Chemother 2005;49:3658\u201362.<\/p>&#13;\n&#13;\n<p>14. Na-Bangchang K, Tan-Ariya P, Thanavibul A, Riengchainam S, Shrestha SB, Karbwang J. Pharmacokinetic and pharmacodynamic interactions of mefloquine and quinine. Int J Clin Pharmacol Res 1999;19:73\u201382.<\/p>&#13;\n&#13;\n<p>15. Newton P, Keeratithakul D, Teja-Isavadharm P, Pukrittayakamee S, Kyle D, White N. Pharmacokinetics of quinine and 3-hydroxyquinine in severe falciparum malaria with acute renal failure. Trans R Soc Trop Med Hyg 1999;93:69\u201372.<\/p>&#13;\n&#13;\n<p>16. Nyunt MM, Lu Y, El-Gasim M, Parsons TL, Petty BG, Hendrix CW. Effects of ritonavir-boosted lopinavir on the pharmacokinetics of quinine. Clin Pharmacol Ther 2012;91:889\u201395.<\/p>&#13;\n&#13;\n<p>17. Pukrittayakamee S, Wanwimolruk S, Stepniewska K, Jantra A, Huyakorn S, Looareesuwan S, et al. Quinine pharmacokinetic\u2013pharmacodynamic relationships in uncomplicated falciparum malaria. Antimicrob Agents Chemother 2003;47:3458\u201363.<\/p>&#13;\n&#13;\n<p>18. Rimchala P, Karbwang J, Sukontason K, Banmairuroi V, Molunto P, Na- Bangchang K. Pharmacokinetics of quinine in patients with chronic renal failure. Eur J Clin Pharmacol 1996;49:497\u2013501.<\/p>&#13;\n&#13;\n<p>19. Roy L, Bannon P, Villeneuve JP. Quinine pharmacokinetics in chronic haemodialysis patients. Br J Clin Pharmacol 2002;54:604\u20139.<\/p>&#13;\n&#13;\n<p>20. Salako LA, Sowunmi A, Akinbami FO. Pharmacokinetics of quinine in African children suffering from kwashiorkor. Br J Clin Pharmacol 1989;28:197\u2013201.<\/p>&#13;\n&#13;\n<p>21. Soyinka JO, Onyeji CO, Omoruyi SI, Owolabi AR, Sarma PV, Cook JM. Effects of concurrent administration of nevirapine on the disposition of quinine in healthy volunteers. J Pharm Pharmacol 2009;61:439\u201343.<\/p>&#13;\n&#13;\n<p>22. Soyinka JO, Onyeji CO, Omoruyi SI, Owolabi AR, Sarma PV, Cook JM. Pharmacokinetic interactions between ritonavir and quinine in healthy volunteers following concurrent administration. Br J Clin Pharmacol 2010;69:262\u201370.<\/p>&#13;\n&#13;\n<p>23. Tarning J, Kloprogge F, Dhorda M, Jullien V, Nosten F, White NJ, et al. Pharmacokinetic properties of artemether, dihydroartemisinin, lumefantrine, and quinine in pregnant women with uncomplicated <em>plasmodium falciparum<\/em> malaria in Uganda. Antimicrob Agents Chemother 2013;57:5096\u2013103.<\/p>&#13;\n&#13;\n<p>24. van Hensbroek MB, Kwiatkowski D, van den Berg B, Hoek FJ, van Boxtel CJ, Kager PA. Quinine pharmacokinetics in young children with severe malaria. Am J Trop Med Hyg 1996;54:237\u201342.<\/p>&#13;\n&#13;\n<p>25. Waller D, Krishna S, Craddock C, Brewster D, Jammeh A, Kwiatkowski D, et al. The pharmacokinetic properties of intramuscular quinine in Gambian children with severe falciparum malaria. Trans R Soc Trop Med Hyg 1990;84:488\u201391.<\/p>&#13;\n&#13;\n<p>26. Wanwimolruk S, Chalcroft S, Coville PF, Campbell AJ. Pharmacokinetics of quinine in young and elderly subjects. Trans R Soc Trop Med Hyg 1991;85:714\u20137.<\/p>&#13;\n&#13;\n<p>27. White NJ, Chanthavanich P, Krishna S, Bunch C, Silamut K. Quinine disposition kinetics. Br J Clin Pharmacol 1983;16:399\u2013403.<\/p>&#13;\n&#13;\n<p>28. Phillips RE, Looareesuwan S, White NJ, Silamut K, Kietinun S, Warrell DA. Quinine pharmacokinetics and toxicity in pregnant and lactating women with falciparum malaria. Br J Clin Pharmacol 1986;21:677\u201383.<\/p>&#13;\n&#13;\n<p>29. Wanwimolruk S, Kang W, Coville PF, Viriyayudhakorn S, Thitiarchakul S. Marked enhancement by rifampicin and lack of effect of isoniazid on the elimination of quinine in man. Br J Clin Pharmacol 1995;40:87\u201391.<\/p>&#13;\n&#13;\n<p>30. Couet W, Laroche R, Floch JJ, Istin B, Fourtillan JB, Sauniere JF. Pharmacokinetics of quinine and doxycycline in patients with acute falciparum malaria: a study in Africa. Ther Drug Monit 1991;13:496\u2013501.<\/p>&#13;\n&#13;\n<p>31. Pussard E, Barennes H, Daouda H, Clavier F, Sani AM, Osse M, et al. Quinine disposition in globally malnourished children with cerebral malaria. Clin Pharmacol Ther 1999;65:500\u201310.<\/p>&#13;\n&#13;\n<p>32. Treluyer JM, Roux A, Mugnier C, Flouvat B, Lagardere B. Metabolism of quinine in children with global malnutrition. Pediatr Res 1996;40:558\u201363.<\/p>&#13;\n&#13;\n<p>33. Viriyayudhakorn S, Thitiarchakul S, Nachaisit S, Ho PC, Wanwimolruk S. Pharmacokinetics of quinine in obesity. Trans R Soc Trop Med Hyg 2000;94:425\u20138.<\/p>&#13;\n&#13;\n<p>34. Guidelines for the treatment of malaria. Second edition. Geneva: World Health Organization; 2010.<\/p>&#13;\n&#13;\n<p>35. Zhao XJ, Ishizaki T. A further interaction study of quinine with clinically important drugs by human liver microsomes: determinations of inhibition constant (Ki) and type of inhibition. Eur J Drug Metab Pharmacokin 1999;24:272\u20138.<\/p>&#13;\n&#13;\n<p>36. Wanwimolruk S, Denton JR. Plasma protein binding of quinine: binding to human serum albumin, alpha 1-acid glycoprotein and plasma from patients with malaria. J Pharm Pharmacol 1992;44:806\u201311.<\/p>&#13;\n&#13;\n<p>37. Karbwang J, Bangchang KN, Thanavibul A, Wattanakoon Y, Harinasuta T. Quinine toxicity when given with doxycycline and mefloquine. Southeast Asian J Trop Med Public Health 1994;25:397\u2013400.<\/p>&#13;\n&#13;\n<p>38. Boland ME, Roper SM, Henry JA. Complications of quinine poisoning. Lancet 1985;i(8425):384\u20135.<\/p>&#13;\n&#13;\n<p>39. Auprayoon P, Sukontason K, Na-Bangchang K, Banmairuroi V, Molunto P, Karbwang J. Pharmacokinetics of quinine in chronic liver disease. Br J Clin Pharmacol 1995;40:494\u20137.<\/p>&#13;\n&#13;\n<p>40. Jacobs F, Nicolaos G, Prieur S, Brivet F. Quinine dosage may not need to be reduced during continuous venovenous hemodiafiltration in severe anuric malaria. Clin Infect Dis 2004;39:288\u20139.<\/p>&#13;\n&#13;\n<p>41. Liotier J, Richard D, Deteix P, Coudore F, Souweine B. Quinine clearance during continuous veno-venous high-volume hemofiltration. Intensive Care Med 2008;34:1925\u20136.<\/p>&#13;\n","title":"A5.12 Quinine","nid":515,"vid":1475,"created":1573123790,"changed":1573197863,"field_content_type":{"tid":2,"name":"Content","class":"content"},"field_operational_":[{"field_image":"","field_link":"","field_title":null}],"field_references":null}